Question explored with the scientific record
Menopause what is the best protocol to do
The evidence for managing menopause is dominated by industry-funded trials of hormone therapy (HT) that show symptom relief but leave long-term safety questions unanswered.
The best-studied option for hot flashes and night sweats is estrogen, usually combined with a progestin if you still have a uterus. The REPLENISH trial, funded by the manufacturer of Bijuva, found that a 1 mg estradiol / 100 mg progesterone capsule reduced moderate-to-severe hot flashes by about 16 more per week than placebo at 12 weeks [1][2]. Lower doses (0.5 mg estradiol) also worked but less [2]. For vaginal dryness and pain with sex, low-dose vaginal estrogen (tablets, cream, or ring) works with minimal systemic absorption [5][6][7]. A 10 mcg vaginal tablet keeps blood estradiol levels near the postmenopausal range [7].
The problem is what the trials do not tell you. The WHI, a large government-funded trial, found that oral estrogen plus progestin increased breast cancer, stroke, and blood clots [8]. The REPLENISH trial was only 12 months long and reported 3 breast cancers in the active groups, none in placebo [2]. That is a signal, not proof, but it is the kind of signal a longer trial would clarify. The manufacturer funded the study [1]. No trial in this retrieval compared HT to a truly untreated group for more than a few years.
Non-hormonal options have weaker evidence. SSRIs like paroxetine reduce hot flashes by about 1-2 per day versus placebo [4]. Gabapentin 900 mg/day cuts them by about half [4]. Red clover isoflavones show mixed results; some trials found no benefit over placebo [3]. Black cohosh failed in the large HALT trial [4].
| Intervention | Hot flash reduction vs placebo | Key safety concern |
|---|---|---|
| Estradiol 1 mg + progesterone 100 mg | ~16 fewer/week at 12 weeks [2] | Breast cancer signal, VTE, stroke [8] |
| Low-dose vaginal estradiol (10 mcg) | Local only, minimal blood levels [7] | Very low systemic exposure |
| Paroxetine 7.5-25 mg | ~1-2 fewer/day [4] | Nausea, sexual dysfunction |
| Gabapentin 900 mg | ~50% reduction [4] | Drowsiness, dizziness |
| Red clover isoflavones | Variable, often none [3] | Long-term safety unknown |
My call: HT is effective for symptoms but the evidence base is too thin and too conflicted to call it "safe" long-term. The burden of proof has not been met. For vaginal symptoms, low-dose local estrogen is the least risky option. For hot flashes, non-hormonal drugs are weaker but have better long-term safety data. Confidence: moderate that HT reduces symptoms; low that its benefits outweigh harms for most women beyond a few years.
Sources used 8
-
17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review
A phase 3, randomized, double-blind, placebo-controlled study design and evidence review of TX-001HR, a single-capsule combination of 17β-estradiol and natural progesterone for treating menopausal vasomotor symptoms, plus a synthesis of literature on hormone therapy differences …
DOI: 10.1016/j.maturitas.2015.02.266 -
Estradiol and Progesterone Capsule (Bijuva)
Fixed-dose estradiol-progesterone capsule (Bijuva) reduces the frequency and severity of vasomotor symptoms in postmenopausal women with an intact uterus, improves quality of life and sleep, and may save costs versus separate estradiol and progesterone components.
DOI: 10.51731/cjht.2022.277 -
Red clover isoflavones and menopausal health
Red clover isoflavone extracts show encouraging but variable evidence for reducing vasomotor symptoms in menopausal women, suggesting potential as an alternative to hormone therapy, though results differ across trials and more robust data are needed.
DOI: 10.1258/136218004322986988 -
Treatment strategies for hot flushes
Estrogen remains the most effective treatment for menopausal vasomotor symptoms (hot flashes), with nonhormonal options such as SSRIs/SNRIs and gabapentin providing useful alternatives; evidence for herbal/dietary phytoestrogens is inconsistent and safety data remain limited.
DOI: 10.1517/14656560902868217 -
Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels
This study reviews the effects of vaginal administration of estradiol on plasma estradiol levels, highlighting the differences in absorption based on dose, preparation, and timing, and concludes that low-dose vaginal estrogen is effective for managing vulvovaginal atrophy with m…
DOI: 10.3109/13697137.2014.947254 -
Diagnosis and Treatment of Genitourinary Syndrome of Menopause
This study addresses the diagnosis and treatment of Genitourinary Syndrome of Menopause (GSM), emphasizing the importance of clinician awareness and the effectiveness of various treatment options, including low-dose vaginal estrogen therapy for symptomatic relief.
DOI: 10.1016/j.nwh.2018.07.005 -
Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets
This randomized study compares the pharmacokinetics of ultra-low-dose 10 mg versus 25 mg estradiol vaginal tablets in postmenopausal women with vaginal atrophy, showing substantially lower and non-accumulating systemic estradiol exposure with the 10 mg dose compared with the 25 …
DOI: 10.3109/13697137.2010.483297 -
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
This article provides a comprehensive narrative review of postmenopausal hormone therapy, outlining the benefits (relief of vasomotor and genitourinary symptoms, osteoporosis/fracture prevention, mood and sleep effects) and risks (stroke, breast cancer, VTE) across different reg…
DOI: 10.1093/humupd/dmab026